Description

IVABRAD 5 MG (1X15)

Indications

Ivabradine 5 mg is primarily indicated for the treatment of chronic stable angina pectoris in patients with a normal sinus rhythm who are unable to tolerate beta-blockers or for whom beta-blockers are contraindicated. It is also used in the management of heart failure in patients with reduced ejection fraction, specifically in those who are in sinus rhythm and have a resting heart rate of 70 beats per minute or more. The medication helps to reduce the frequency of angina episodes and improve exercise tolerance.

Mechanism of Action

Ivabradine works by selectively inhibiting the If (funny) current in the sinoatrial node, which is responsible for regulating heart rate. By blocking this current, Ivabradine decreases heart rate without affecting myocardial contractility or blood pressure. This reduction in heart rate leads to decreased myocardial oxygen demand, which is particularly beneficial in patients with angina. The drug’s mechanism allows for improved coronary perfusion and oxygen delivery to the myocardium during diastole, thus alleviating symptoms of angina.

Pharmacological Properties

Ivabradine is classified as a selective sinus node inhibitor. It has a unique pharmacokinetic profile, with an oral bioavailability of approximately 40% and a peak plasma concentration achieved within 1 to 2 hours after administration. The drug is extensively metabolized by the liver, primarily via the cytochrome P450 3A4 enzyme system. Its elimination half-life is around 2 hours, with a steady-state concentration reached within 3 to 5 days of continuous dosing. The renal excretion of unchanged drug is minimal, with most metabolites being excreted in the feces.

Contraindications

Ivabradine is contraindicated in patients with acute decompensated heart failure, severe hypotension, bradycardia (heart rate less than 60 beats per minute), sick sinus syndrome, and in patients with pacemakers that control heart rate. It is also contraindicated in patients with known hypersensitivity to Ivabradine or any of its components. Additionally, the use of Ivabradine is not recommended in combination with strong CYP3A4 inhibitors, as this may lead to increased plasma concentrations and a higher risk of side effects.

Side Effects

The most common side effects associated with Ivabradine include bradycardia, hypertension, and visual disturbances such as phosphenes, which are transient flashes of light. Other potential side effects may include dizziness, fatigue, and headache. Serious side effects, although rare, can include atrial fibrillation and other arrhythmias. Patients should be monitored for these adverse effects, especially during the initial stages of treatment or when dosage adjustments are made.

Dosage and Administration

The recommended starting dose of Ivabradine is 5 mg taken orally twice daily, with or without food. After at least two weeks of treatment, the dose may be adjusted based on heart rate and clinical response. The maximum recommended dose is 7.5 mg twice daily. It is important for patients to adhere to the prescribed dosing schedule and to consult their healthcare provider before making any changes to their medication regimen.

Interactions

Ivabradine has several notable drug interactions. Concomitant use with strong CYP3A4 inhibitors such as ketoconazole, itraconazole, and certain HIV protease inhibitors can significantly increase Ivabradine plasma levels, leading to an increased risk of bradycardia and other side effects. Conversely, medications that induce CYP3A4, such as rifampicin and St. John’s Wort, may reduce the effectiveness of Ivabradine. Patients should inform their healthcare provider of all medications they are taking, including over-the-counter drugs and herbal supplements, to avoid potential interactions.

Precautions

Patients taking Ivabradine should be monitored for heart rate, especially during the initiation of therapy and after any dose adjustments. Caution is advised in patients with a history of atrial fibrillation or other arrhythmias. Additionally, Ivabradine should be used with caution in patients with hepatic impairment, as the drug is primarily metabolized by the liver. It is not recommended for use in patients with severe hepatic impairment. Pregnant or breastfeeding women should consult their healthcare provider before using Ivabradine, as the safety of the drug in these populations has not been established.

Clinical Studies

Clinical studies have demonstrated the efficacy of Ivabradine in reducing the frequency of angina episodes and improving exercise tolerance in patients with chronic stable angina. In the BEAUTIFUL trial, Ivabradine was shown to significantly reduce the risk of cardiovascular events in patients with coronary artery disease and left ventricular dysfunction. Another study, the SHIFT trial, confirmed the benefits of Ivabradine in heart failure patients, showing a reduction in hospitalization rates and mortality among those treated with Ivabradine compared to placebo. These studies support the use of Ivabradine as an effective therapeutic option in specific patient populations.

Conclusion

Ivabradine 5 mg is a valuable medication for the management of chronic stable angina and heart failure in appropriately selected patients. Its unique mechanism of action, which selectively reduces heart rate, provides an alternative for those who cannot tolerate beta-blockers. While generally well-tolerated, it is important for healthcare providers to monitor patients for potential side effects and drug interactions. As with any medication, a thorough assessment of the patient’s medical history and current medications is essential to ensure safe and effective treatment.